(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...

Scott Brooks, from Maltby, was just 17 when he started smoking, saying it was just "the norm" for the 1980s. But after ...

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...

A 2026 informational report on the Herz P1 Smart Oximeter fingertip pulse oxygen monitor, covering the company's FDA 510(k) cleared positioning, ±2% SpO2 blood oxygen accuracy specifications, smart ...

AeroDel’s founders, Zahir Jaffer, Shradha Sangwai and K.K.Suraj Rajan, have one common denominator: asthma. This led them to ...

UK government drives forward its 150-day clinical trial target: United Kingdom Friday, April 17, 2026, 09:00 Hrs [IST] NHS patients will be able to access life-changing new treatm ...

Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions. It does so by reducing inflammation signals in your immune system. Your response to this drug may vary ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...